Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 304
Filtrer
1.
J Am Chem Soc ; 145(34): 19129-19139, 2023 08 30.
Article de Anglais | MEDLINE | ID: mdl-37556835

RÉSUMÉ

Discovering new bioactive molecules is crucial for drug development. Finding a hit compound for a new drug target usually requires screening of millions of molecules. Affinity selection based technologies have revolutionized early hit discovery by enabling the rapid screening of libraries with millions or billions of compounds in short timeframes. In this Perspective, we describe recent technology breakthroughs that enable the screening of ultralarge synthetic peptidomimetic libraries with a barcode-free tandem mass spectrometry decoding strategy. A combination of combinatorial synthesis, affinity selection, automated de novo peptide sequencing algorithms, and advances in mass spectrometry instrumentation now enables hit discovery from synthetic libraries with over 100 million members. We provide a perspective on this powerful technology and showcase success stories featuring the discovery of high affinity binders for a number of drug targets including proteins, nucleic acids, and specific cell types. Further, we show the usage of the technology to discover synthetic peptidomimetics with specific functions and reactivity. We predict that affinity selection coupled with tandem mass spectrometry and automated de novo decoding will rapidly evolve further and become a broadly used drug discovery technology.


Sujet(s)
Bibliothèques de petites molécules , Spectrométrie de masse en tandem , Spectrométrie de masse en tandem/méthodes , Bibliothèques de petites molécules/composition chimique , Découverte de médicament , Séquence d'acides aminés
2.
BMJ Mil Health ; 2023 May 23.
Article de Anglais | MEDLINE | ID: mdl-37220991

RÉSUMÉ

INTRODUCTION: Little is known of the epidemiology of musculoskeletal injuries (MSKIs) in US Air Force Special Warfare (AFSPECWAR) Tactical Air Control Party trainees. The purpose of this longitudinal retrospective cohort study was to (1) report the incidence and type of MSKI sustained by AFSPECWAR trainees during and up to 1 year following training, (2) identify factors associated with MSKI, and (3) develop and present the MSKI classification matrix used to identify and categorise injuries in this study. METHODS: Trainees in the Tactical Air Control Party Apprentice Course between fiscal years 2010-2020 were included. Diagnosis codes were classified as MSKI or non-MSKI using a classification matrix. Incidence rates and incidence proportion for injury types and regions were calculated. Measures were compared for differences between those who did and did not sustain an MSKI during training. A Cox proportional hazards model was used to identify factors associated with MSKI. RESULTS: Of the 3242 trainees, 1588 (49%) sustained an MSKI during training and the cohort sustained MSKIs at a rate of 16 MSKI per 100 person-months. Overuse/non-specific lower extremity injuries predominated. Differences were seen in some baseline measures between those who did and did not sustain an MSKI. Factors retained in the final Cox regression model were age, 1.5-mile run times and prior MSKI. CONCLUSION: Slower run times and higher age were associated with an increased likelihood of MSKI. Prior MSKI was the strongest predictor of MSKI during training. Trainees sustained MSKIs at a higher rate than graduates in their first year in the career field. The MSKI matrix was effective in identifying and categorising MSKI over a prolonged (12-year) surveillance period and could be useful for future injury surveillance efforts in the military or civilian settings. Findings from this study could inform future injury mitigation efforts in military training environments.

3.
Clin. transl. oncol. (Print) ; 23(10): 2099-2108, oct. 2021. graf
Article de Anglais | IBECS | ID: ibc-223380

RÉSUMÉ

Purpose We aimed to evaluate the current situation of electronic health records (EHRs) and patient registries in the oncology departments of hospitals in Spain. Methods This was a cross-sectional study conducted from December 2018 to September 2019. The survey was designed ad hoc by the Outcomes Evaluation and Clinical Practice Section of the Spanish Society of Medical Oncology (SEOM) and was distributed to all head of medical oncology department members of SEOM. Results We invited 148 heads of oncology departments, and 81 (54.7%) questionnaires were completed, with representation from all 17 Spanish autonomous communities. Seventy-seven (95%) of the respondents had EHRs implemented at their hospitals; of them, over 80% considered EHRs to have a positive impact on work organization and clinical practice, and 73% considered that EHRs improve the quality of patient care. In contrast, 27 (35.1%) of these respondents felt that EHRs worsened the physician–patient relationship and conveyed an additional workload (n = 29; 37.6%). Several drawbacks in the implementation of EHRs were identified, including the limited inclusion of information on both outpatients and inpatients, information recorded in free text data fields, and the availability of specific informed consent. Forty-six (56.7%) respondents had patient registries where they recorded information from all patients seen in the department. Conclusion Our study indicates that EHRs are almost universally implemented in the hospitals surveyed and are considered to have a positive impact on work organization and clinical practice. However, EHRs currently have several drawbacks that limit their use for investigational purposes (AU)


Sujet(s)
Humains , Service hospitalier d'oncologie/statistiques et données numériques , Dossiers médicaux électroniques , Oncologie médicale/statistiques et données numériques , Attitude du personnel soignant , Prescription électronique , Relations médecin-patient , Qualité des soins de santé , Études transversales , Enquêtes et questionnaires , Espagne
4.
Clin. transl. oncol. (Print) ; 23(8): 1511-1519, ago. 2021.
Article de Anglais | IBECS | ID: ibc-222149

RÉSUMÉ

Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by the regulatory agencies, nivolumab and pembrolizumab are paradigmatic as the most relevant ones according to the magnitude of available data derived from the extensive preclinical and clinical experience. Although in both cases the respective data sheets indicate well-defined dosage regimens, a review of the literature permits to verify the existence of many issues still unresolved about dosing the two agents, so it must be considered an open question of potentially important consequences, in which to work to improve the effectiveness and efficiency of use (AU)


Sujet(s)
Humains , Anticorps monoclonaux humanisés/administration et posologie , Antinéoplasiques immunologiques/administration et posologie , Tumeurs/traitement médicamenteux , Nivolumab/administration et posologie , Anticorps monoclonaux humanisés/pharmacocinétique , Antinéoplasiques/pharmacocinétique , Antinéoplasiques immunologiques/pharmacocinétique , Nivolumab/pharmacocinétique
5.
Clin Transl Oncol ; 23(10): 2099-2108, 2021 Oct.
Article de Anglais | MEDLINE | ID: mdl-33864619

RÉSUMÉ

PURPOSE: We aimed to evaluate the current situation of electronic health records (EHRs) and patient registries in the oncology departments of hospitals in Spain. METHODS: This was a cross-sectional study conducted from December 2018 to September 2019. The survey was designed ad hoc by the Outcomes Evaluation and Clinical Practice Section of the Spanish Society of Medical Oncology (SEOM) and was distributed to all head of medical oncology department members of SEOM. RESULTS: We invited 148 heads of oncology departments, and 81 (54.7%) questionnaires were completed, with representation from all 17 Spanish autonomous communities. Seventy-seven (95%) of the respondents had EHRs implemented at their hospitals; of them, over 80% considered EHRs to have a positive impact on work organization and clinical practice, and 73% considered that EHRs improve the quality of patient care. In contrast, 27 (35.1%) of these respondents felt that EHRs worsened the physician-patient relationship and conveyed an additional workload (n = 29; 37.6%). Several drawbacks in the implementation of EHRs were identified, including the limited inclusion of information on both outpatients and inpatients, information recorded in free text data fields, and the availability of specific informed consent. Forty-six (56.7%) respondents had patient registries where they recorded information from all patients seen in the department. CONCLUSION: Our study indicates that EHRs are almost universally implemented in the hospitals surveyed and are considered to have a positive impact on work organization and clinical practice. However, EHRs currently have several drawbacks that limit their use for investigational purposes. CLINICAL TRIAL REGISTRATION: Not applicable.


Sujet(s)
Dossiers médicaux électroniques/statistiques et données numériques , Oncologie médicale/statistiques et données numériques , Service hospitalier d'oncologie/statistiques et données numériques , Enregistrements/statistiques et données numériques , Attitude du personnel soignant , Études transversales , Prescription électronique/statistiques et données numériques , Humains , Relations médecin-patient , Qualité des soins de santé , Espagne , Enquêtes et questionnaires/statistiques et données numériques , Charge de travail
6.
Clin Transl Oncol ; 23(8): 1511-1519, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-33583005

RÉSUMÉ

Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by the regulatory agencies, nivolumab and pembrolizumab are paradigmatic as the most relevant ones according to the magnitude of available data derived from the extensive preclinical and clinical experience. Although in both cases the respective data sheets indicate well-defined dosage regimens, a review of the literature permits to verify the existence of many issues still unresolved about dosing the two agents, so it must be considered an open question of potentially important consequences, in which to work to improve the effectiveness and efficiency of use.


Sujet(s)
Anticorps monoclonaux humanisés/administration et posologie , Antinéoplasiques immunologiques/administration et posologie , Inhibiteurs de points de contrôle immunitaires/administration et posologie , Tumeurs/traitement médicamenteux , Nivolumab/administration et posologie , Anticorps monoclonaux humanisés/pharmacocinétique , Anticorps monoclonaux humanisés/usage thérapeutique , Antinéoplasiques immunologiques/pharmacocinétique , Antinéoplasiques immunologiques/usage thérapeutique , Humains , Inhibiteurs de points de contrôle immunitaires/usage thérapeutique , Immunothérapie adoptive/méthodes , Nivolumab/pharmacocinétique , Nivolumab/usage thérapeutique , Récepteur-1 de mort cellulaire programmée/antagonistes et inhibiteurs
7.
Antibiotics (Basel) ; 10(2)2021 Jan 30.
Article de Anglais | MEDLINE | ID: mdl-33573154

RÉSUMÉ

Nine new complexes with camphor imine or camphor sulfonimine ligands were synthesized and analytically and spectroscopically characterized, aiming to identify the key parameters that drive the antibacterial activity of the complexes with metal cores and imine substituents with distinct electronic and steric characteristics. The antimicrobial activity of all complexes was evaluated by determining their minimum inhibitory concentrations (MIC) against the Gram-negative Escherichia coli ATCC25922, Pseudomonas aeruginosa 477, and Burkholderia contaminans IST408, and the Gram-positive Staphylococcus aureus Newman. Camphor imine complexes based on the hydroxyl silver center ({Ag(OH)}) typically perform better than those based on the nitrate silver center ({Ag(NO3)}), while ligands prone to establish hydrogen bonding facilitate interactions with the bacterial cell surface structures. A different trend is observed for the silver camphor sulfonimine complexes that are almost non-sensitive to the nature of the metal cores {Ag(OH)} or {Ag(NO3)} and display low sensitivity to the Y substituent. The antibacterial activities of the Ag(I) camphor sulfonimine complexes are higher than those of the camphor imine analogues. All the complexes display higher activity towards Gram-negative strains than towards the Gram-positive strain.

8.
Int J Pharm ; 593: 120110, 2021 Jan 25.
Article de Anglais | MEDLINE | ID: mdl-33246052

RÉSUMÉ

Wound care remains a challenge in healthcare. This work aimed to develop a new polyvinyl alcohol (PVA)/chitosan (Ch) based wound dressing able to ensure protection, hydration and a controlled release of antiseptics, as alternative to actual treatments. Two distinct formulations (1:1 and 3:1, w/w) were prepared, sterilized by autoclaving and characterized concerning surface morphology, degradation over the time, mechanical properties and hydrophilicity. Both dressings revealed adequate properties for the intended purpose. The dressings were loaded with chlorhexidine (CHX) and polyhexanide (PHMB) and the drug release profiles were determined using Franz diffusion cells. The release of PHMB was more sustained than CHX, lasting for 2 days. As the amounts of drugs released by PVA/Ch 1:1 were greater, the biological tests were done only with this formulation. The drug loaded dressings revealed antibacterial activity against S. aureus and S. epidermidis, but only the ones loaded with PHMB showed adequate properties in terms of cytotoxicity and irritability. The application of this elastic dressing in the treatment of wounds in a dog led to faster recovery than conventional treatment, suggesting that the material can be a promising alternative in wound care.


Sujet(s)
Anti-infectieux locaux , Chitosane , Animaux , Antibactériens/pharmacologie , Bandages , Chiens , Poly(alcool vinylique) , Staphylococcus aureus , Cicatrisation de plaie
9.
BJS Open ; 4(5): 830-839, 2020 10.
Article de Anglais | MEDLINE | ID: mdl-32762036

RÉSUMÉ

BACKGROUND: Laparoscopic subtotal gastrectomy (LSG) for cancer is associated with good perioperative outcomes and superior quality of life compared with the open approach, albeit at higher cost. An economic evaluation was conducted to compare the two approaches. METHODS: A cost-effectiveness analysis between LSG and open subtotal gastrectomy (OSG) for gastric cancer was performed using a decision-tree cohort model with a healthcare system perspective and a 12-month time horizon. Model inputs were informed by a meta-analysis of relevant literature, with costs represented in 2016 Canadian dollars (CAD) and outcomes measured in quality-adjusted life-years (QALYs). A secondary analysis was conducted using inputs extracted solely from European and North American studies. Deterministic (DSA) and probabilistic (PSA) sensitivity analyses were performed. RESULTS: In the base-case model, costs of LSG were $935 (€565) greater than those of OSG, with an incremental gain of 0·050 QALYs, resulting in an incremental cost-effectiveness ratio of $18 846 (€11 398) per additional QALY gained from LSG. In the DSA, results were most sensitive to changes in postoperative utility, operating theatre and equipment costs, as well as duration of surgery and hospital stay. PSA showed that the likelihood of LSG being cost-effective at willingness-to-pay thresholds of $50 000 (€30 240) per QALY and $100 000 (€60 480) per QALY was 64 and 68 per cent respectively. Secondary analysis using European and North American clinical inputs resulted in LSG being dominant (cheaper and more effective) over OSG, largely due to reduced length of stay after LSG. CONCLUSION: In this decision analysis model, LSG was cost-effective compared with OSG for gastric cancer.


ANTECEDENTES: Pese a su mayor coste, la gastrectomía subtotal laparoscópica se asocia con buenos resultados perioperatorios y una mejor calidad de vida en comparación con la cirugía abierta en el tratamiento del cáncer. Se realizó una evaluación económica comparando los dos abordajes. MÉTODOS: Se efectuó un análisis de coste-efectividad de la gastrectomía subtotal laparoscópica (laparoscopic subtotal gastrectomy, LSG) o de la gastrectomía subtotal abierta (open subtotal gastrectomy, OSG) en el cáncer gástrico utilizando un modelo de cohortes con árbol de decisión desde la perspectiva del sistema de salud y con un horizonte temporal de 12 meses. Los gastos del modelo fueron evaluados tras un metaanálisis de literatura relevante y expresados en dólares canadienses (Canadian dollars, CAD) del 2016. Los resultados se midieron en años de vida ajustados por su calidad (quality-adjusted life years, QALYs). Se realizó un análisis secundario utilizando los datos extraídos únicamente de estudios europeos y norteamericanos. Además, se realizaron análisis de sensibilidad determinístico y probabilístico (deterministic and probabilistic sensitivity analyses, DSA y PSA). RESULTADOS: En el modelo del caso base, los costes de la LSG fueron de 934,78$ (565€) más que en la OSG, con una ganancia incremental de 0,050 QALYs, que supuso una relación coste-efectividad incremental (incremental cost-effectiveness ratio, ICER) de 18.846,12$ (11.398€) por QALY adicional en la LSG. En el DSA, los resultados fueron más sensibles a cambios en el postoperatorio, quirófano y coste de los equipos, así como en la duración de la intervención y la hospitalización. El PSA demostró que la probabilidad de que la LSG fuera rentable en términos de disposición de pago (willingness-to-pay, WTP) para dos umbrales, de 50.000$ (30.240€) y 100.000$ (60.480€) por QALY fue del 64% y del 68%, respectivamente. En el análisis secundario utilizando los datos europeos y norteamericanos se demostró que la LSG era claramente dominante (más barata y más efectiva) que la OSG, en gran parte debido a la reducción de la estancia hospitalaria de la LSG. CONCLUSIÓN: En este modelo de análisis de decisión, la LSG fue coste-efectiva en comparación con la OSG para el cáncer gástrico.


Sujet(s)
Adénocarcinome/chirurgie , Analyse coût-bénéfice , Gastrectomie/méthodes , Laparoscopie/méthodes , Tumeurs de l'estomac/chirurgie , Adénocarcinome/économie , Gastrectomie/économie , Humains , Laparoscopie/économie , Années de vie ajustées sur la qualité , Essais contrôlés randomisés comme sujet , Tumeurs de l'estomac/économie
10.
Theriogenology ; 151: 16-27, 2020 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-32251936

RÉSUMÉ

The objective of the present study was to evaluate the effect of equine chorionic gonadotropin (eCG) administration associated to different proestrus lengths for Fixed-time AI (FTAI) in beef heifers. In Experiment 1, pre-pubertal heifers (n = 46) received a 6-day estradiol/progesterone-based treatment (J-Synch protocol), and were then allocated into four experimental groups in a 2 × 2 factorial design, to receive or not receive eCG (300 IU) at the time of intravaginal progesterone device removal, and to receive GnRH at 48 h or 72 h after device removal (to induce shortened and prolonged proestrus length, respectively). Endometrial samples were obtained 6 d after ovulation from the cranial portion of the uterine horn. The eCG administration induced greater serum estradiol-17ß concentrations before ovulation (P < 0.05) and greater proportion of heifers bearing a competent corpus luteum after ovulation (P = 0.054). Delaying GnRH administration from 48 h to 72 h induced a longer interval from device removal to ovulation (i.e., prolonged proestrus; P < 0.05), larger diameter of the ovulatory follicle, and greater progesterone concentrations on Day 10-11 after ovulation. Heifers in eCG + GnRH72h group had more uterine receptors in luminal epithelium than those in eCG + GnRH48h group (PR and ERα), and than those in No eCG + GnRH72h group (PR) (P < 0.05). No effect of eCG or GnRH treatments was found in endometrial gene expression of progesterone and estrogen receptors. In Experiment 2, a total of 2,598 heifers received the J-Synch protocol associated or not with eCG administration at device removal, followed by FTAI/GnRH at 60 or 72 h after device removal (i.e., prolonged proestrus protocol). Heifers that received eCG had greater P/AI than those not receiving eCG (P < 0.05) and there was an interaction between eCG treatment and time of FTAI. The lowest P/AI was found in those heifers that received FTAI/GnRH at 72 h without eCG treatment at device removal (P < 0.05), and no differences were found between the other experimental groups. In conclusion, prolonging the length of proestrus in J-Synch protocol improves ovulatory follicular diameter and luteal function; and the administration of eCG at device removal improves preovulatory estradiol concentrations and luteal function. Finally, P/AI was enhanced by eCG treatment and the improvement was more evident when FTAI/GnRH was performed at 72 h after device removal.


Sujet(s)
Bovins , Gonadotrophine chorionique/pharmacologie , Ovulation/effets des médicaments et des substances chimiques , Utérus/effets des médicaments et des substances chimiques , Animaux , Synchronisation de l'oestrus/méthodes , Femelle , Insémination artificielle/médecine vétérinaire , Follicule ovarique/effets des médicaments et des substances chimiques , Induction d'ovulation/médecine vétérinaire , Grossesse , Taux de grossesse , Utérus/physiologie
11.
Clin Transl Oncol ; 22(8): 1205-1215, 2020 Aug.
Article de Anglais | MEDLINE | ID: mdl-31898053

RÉSUMÉ

Over the last 2 decades, the standard fluoropyrimidine-based chemotherapy backbone for metastatic colorectal cancer has been complemented by the addition of novel biological agents, achieving impressive increases in 5-year survival rates. Nonetheless, these new combinations have also entailed increases in toxicity, leading to evaluation of de-escalated chemotherapy regimens and "drug holiday" periods in attempts to reduce side effects and optimise quality of life without impairing efficacy. Here, we review the current and emerging evidence for maintenance schedules with chemotherapy and targeted agents, versus continuous treatment after induction treatment, in metastatic colorectal cancer patients.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Chimiothérapie de maintenance/méthodes , Antinéoplasiques/administration et posologie , Antinéoplasiques/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Bévacizumab/administration et posologie , Camptothécine/administration et posologie , Camptothécine/analogues et dérivés , Capécitabine/administration et posologie , Cétuximab/administration et posologie , Essais cliniques comme sujet , Tumeurs colorectales/anatomopathologie , Évolution de la maladie , Chlorhydrate d'erlotinib/administration et posologie , Fluorouracil/administration et posologie , Fluorouracil/effets indésirables , Humains , Chimiothérapie d'induction , Irinotécan/administration et posologie , Leucovorine/administration et posologie , Leucovorine/effets indésirables , Maladies du système nerveux/induit chimiquement , Maladies du système nerveux/prévention et contrôle , Composés organiques du platine/administration et posologie , Composés organiques du platine/effets indésirables , Oxaliplatine/administration et posologie , Oxaliplatine/effets indésirables , Oxaloacétates/administration et posologie , Panitumumab/administration et posologie , Abstention thérapeutique
12.
Reprod Fertil Dev ; 30(11): 1541-1552, 2018 Oct.
Article de Anglais | MEDLINE | ID: mdl-29778102

RÉSUMÉ

The aim of the present study was to investigate the effects of a strategy for extending pro-oestrus (the interval between luteolysis and ovulation) in an oestrus synchronisation protocol (named J-Synch) in beef heifers on follicular growth, sexual steroid concentrations, the oestrogen receptor ERα and progesterone receptors (PR) in the uterus, insulin-like growth factor (IGF) 1 and pregnancy rates. In Experiment 1, heifers treated with the new J-Synch protocol had a longer pro-oestrus period than those treated with the conventional protocol (mean (±s.e.m.) 93.7±12.9 vs 65.0±13.7h respectively; P<0.05). The rate of dominant follicle growth from the time of progesterone device removal to ovulation was greater in heifers in the J-Synch than conventional group (P<0.05). Luteal area and serum progesterone concentrations were greater in the J-Synch Group (P<0.05) for the 12 days after ovulation. Progesterone receptor (PGR) staining on Day 6 after ovulation in the uterine stroma was lower in the J-Synch than conventional group (P<0.05), and the expression of PR gene (PGR) and IGF1 gene tended to be lower in J-Synch-treated heifers (P<0.1). In Experiment 2 (n=2349), the pregnancy rate 30-35 days after fixed-time AI (FTAI) was greater for heifers in the J-Synch than conventional group (56.1% vs 50.7% respectively). In conclusion, our strategy for extending pro-oestrus (i.e. the J-Synch protocol) significantly improves pregnancy establishment in beef heifers. This improvement was related to an increased rate of growth of the dominant ovulatory follicle, greater progesterone concentrations during the ensuing luteal phase and different uterine patterns of PGR and IGF1, which may have favoured embryo development and pregnancy establishment.


Sujet(s)
Oestradiol/analogues et dérivés , Synchronisation de l'oestrus/physiologie , Ovaire/physiologie , Prooestrus/physiologie , Progestérone/administration et posologie , Utérus/physiologie , Animaux , Bovins , Oestradiol/administration et posologie , Oestradiol/sang , Synchronisation de l'oestrus/effets des médicaments et des substances chimiques , Femelle , Follicule ovarique/imagerie diagnostique , Follicule ovarique/effets des médicaments et des substances chimiques , Ovaire/imagerie diagnostique , Ovaire/effets des médicaments et des substances chimiques , Grossesse , Prooestrus/effets des médicaments et des substances chimiques , Progestérone/sang , Récepteurs des oestrogènes/métabolisme , Récepteurs à la progestérone/métabolisme , Utérus/imagerie diagnostique , Utérus/effets des médicaments et des substances chimiques
14.
Acta Anaesthesiol Scand ; 62(5): 620-627, 2018 May.
Article de Anglais | MEDLINE | ID: mdl-29377065

RÉSUMÉ

BACKGROUND: Pre-operative complex carbohydrate (CHO) drinks are recommended to attenuate post-operative insulin resistance. However, many institutions use simple CHO drinks, which while convenient, may have less metabolic effects. Whey protein may enhance insulin release when added to complex CHO. The aim of this study was to compare the insulin response to simple CHO vs. simple CHO supplemented with whey protein. METHODS: Twelve healthy volunteers participated in this double-blinded, within subject, cross-over design study investigating insulin response to simple CHO drink vs. simple CHO + whey (CHO + W) drink. The primary outcome was the accumulated insulin response during 180 min after ingestion of the drinks (Area under the curve, AUC). Secondary outcomes included plasma glucose and ghrelin levels, and gastric emptying rate estimated by acetaminophen absorption technique. Data presented as mean (SD). RESULTS: There was no differences in accumulated insulin response after the CHO or CHO + W drinks [AUC: 15 (8) vs. 20 (14) nmol/l, P = 0.27]. Insulin and glucose levels peaked between 30 and 60 min and reached 215 (95) pmol/l and 7 (1) mmol/l after the CHO drink and to 264 (232) pmol/l and 6.5 (1) mmol/l after the CHO + W drink. There were no differences in glucose or ghrelin levels or gastric emptying with the addition of whey. CONCLUSION: The addition of whey protein to a simple CHO drink did not change the insulin response in healthy individuals. The peak insulin responses to simple CHO with or without whey protein were lower than that previously reported with complex CHO drinks. The impact of simple carbohydrate drinks with lower insulin response on peri-operative insulin sensitivity requires further study.


Sujet(s)
Glycémie/analyse , Hydrates de carbone alimentaires/administration et posologie , Insuline/sang , Protéines de lactosérum/administration et posologie , Adulte , Sujet âgé , Études croisées , Méthode en double aveugle , Vidange gastrique , Ghréline/sang , Humains , Adulte d'âge moyen
15.
Obes Rev ; 19(5): 638-653, 2018 05.
Article de Anglais | MEDLINE | ID: mdl-29334693

RÉSUMÉ

Findings on the relationship between family meal frequency and children's nutritional health are inconsistent. The reasons for these mixed results have to date remained largely unexplored. This systematic review and meta-analysis of 57 studies (203,706 participants) examines (i) the relationship between family meal frequency and various nutritional health outcomes and (ii) two potential explanations for the inconsistent findings: sociodemographic characteristics and mealtime characteristics. Separate meta-analyses revealed significant associations between higher family meal frequency and better overall diet quality (r = 0.13), more healthy diet (r = 0.10), less unhealthy diet (r = -0.04) and lower body mass index, BMI (r = -0.05). Child's age, country, number of family members present at meals and meal type (i.e. breakfast, lunch or dinner) did not moderate the relationship of meal frequency with healthy diet, unhealthy diet or BMI. Socioeconomic status only moderated the relationship with BMI. The findings show a significant relationship between frequent family meals and better nutritional health - in younger and older children, across countries and socioeconomic groups, and for meals taken with the whole family vs. one parent. Building on these findings, research can now target the causal direction of the relationship between family meal frequency and nutritional health.


Sujet(s)
Comportement alimentaire/physiologie , Repas , Valeur nutritive/physiologie , Obésité pédiatrique/prévention et contrôle , Indice de masse corporelle , Enfant , Phénomènes physiologiques nutritionnels chez l'enfant , Famille , Humains , Parents/enseignement et éducation , Obésité pédiatrique/épidémiologie , Facteurs socioéconomiques , Facteurs temps
18.
Nanoscale ; 9(44): 17263-17273, 2017 Nov 16.
Article de Anglais | MEDLINE | ID: mdl-29090302

RÉSUMÉ

Herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1) represent the two most frequent sexually transmitted infections (STI) worldwide. Epidemiological studies suggest that HSV-2 increases the risk of HIV-1 acquisition approximately 3-fold mainly due to the clinical and immunological manifestations. In the absence of vaccines against both STI, the development of new preventive strategies has become essential for further studies. We performed the screening of six novel polyanionic carbosilane dendrons to elucidate their potential activity against HSV-2/HIV-1 co-infection and their mechanism of action. These new nanoparticles are carbosilane branched dendrons from first to third generation, with palmitic or hexanoic fatty acids as the core and capped with sulfonate groups, named G1d-STE2Hx, G2d-STE4Hx, G3d-STE8Hx, G1d-STE2Pm, G2d-STE4Pm and G3d-STE8Pm. G3d-STE8Hx and G3d-STE8Pm carbosilane branched dendrons showed high viability. These dendrons also showed a great broad-spectrum antiviral activity, as well as a suitable efficacy against HIV-1 even if the mucosal disruption occurs as a consequence of HSV-2 infection. Our results exert high inhibition against HSV-2 and HIV-1 by blocking the entry of both viruses with the median effective concentration EC50 values in the nanomolar range. Additionally, G3d-STE8Hx and G3d-STE8Pm retained their anti-HSV-2/HIV-1 activity at different pH values. G3d-STE8Hx and G3d-STE8Pm dendrons may be potential candidates as dual-acting microbicides against HSV-2/HIV-1 co-infection.


Sujet(s)
Antiviraux/pharmacologie , Dendrimères/composition chimique , Acides gras/composition chimique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/effets des médicaments et des substances chimiques , Herpèsvirus humain de type 2/effets des médicaments et des substances chimiques , Silanes/pharmacologie , Animaux , Chlorocebus aethiops , Co-infection/traitement médicamenteux , Co-infection/virologie , Infections à VIH/traitement médicamenteux , Herpès génital/traitement médicamenteux , Humains , Plantes médicinales , Cellules Vero
19.
Clin Transl Oncol ; 19(9): 1067-1078, 2017 Sep.
Article de Anglais | MEDLINE | ID: mdl-28342058

RÉSUMÉ

This Galician consensus statement is a joint oncologists/cardiologists initiative indented to establish basic recommendations on how to prevent and to manage the cardiotoxicity in breast cancer with the aim of ensuring an optimal cardiovascular care of these patients. A clinical screening of the patients before treatment is recommended to stratify them into a determined risk group based on their intrinsic cardiovascular risk factors and those extrinsic arose from breast cancer therapy, thereby providing individualized preventive and monitoring measures. Suitable initial and ongoing assessments for patients with low and moderate/high risk and planned treatment with anthracyclines and trastuzumab are given; also, measures aimed at preventing and correcting any modifiable risk factor are pointed out .


Sujet(s)
Antinéoplasiques/effets indésirables , Tumeurs du sein/traitement médicamenteux , Cardiotoxicité/prévention et contrôle , Cardiotoxicité/étiologie , Femelle , Humains , Facteurs de risque
20.
J Biomed Mater Res B Appl Biomater ; 105(7): 1799-1807, 2017 10.
Article de Anglais | MEDLINE | ID: mdl-27192551

RÉSUMÉ

In this article, liposome-based coatings aiming to control drug release from therapeutic soft contact lenses (SCLs) materials are analyzed. A PHEMA based hydrogel material loaded with levofloxacin is used as model system for this research. The coatings are formed by polyelectrolyte layers containing liposomes of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and DMPC + cholesterol (DMPC + CHOL). The effect of friction and temperature on the drug release is investigated. The aim of the friction tests is to simulate the blinking of the eyelid in order to verify if the SCLs materials coated with liposomes are able to keep their properties, in particular the drug release ability. It was observed that under the study conditions, friction did not affect significantly the drug release from the liposome coated PHEMA material. In contrast, increasing the temperature of release leads to an increase of the drug diffusion rate through the hydrogel. This phenomenon is recorded both in the control and in the coated samples. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 1799-1807, 2017.


Sujet(s)
Clignement , Cholestérol , Matériaux revêtus, biocompatibles , Lentilles de contact hydrophiles , Dimyristoylphosphatidylcholine , Cholestérol/composition chimique , Cholestérol/pharmacocinétique , Cholestérol/pharmacologie , Matériaux revêtus, biocompatibles/composition chimique , Matériaux revêtus, biocompatibles/pharmacocinétique , Matériaux revêtus, biocompatibles/pharmacologie , Préparations à action retardée/composition chimique , Préparations à action retardée/pharmacocinétique , Préparations à action retardée/pharmacologie , Dimyristoylphosphatidylcholine/composition chimique , Dimyristoylphosphatidylcholine/pharmacocinétique , Dimyristoylphosphatidylcholine/pharmacologie , Température élevée , Humains , Liposomes
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE